Ocular Therapeutix, Inc.
Here’s whether Ocular Therapeutix, Inc. (OCUL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); strong 1-year return of +37.0%. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-2.34% over 10 days); RSI 73 — overbought, elevated pullback risk; 3-month momentum negative (-12.9%). Currently 40.3% off its 52-week high. Score: -3/7.
OCUL is trading below its 200-day MA ($11.10) — a key warning sign the longer-term trend is under pressure. With an RSI of 72.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +37.0% compares to +35.1% for SPY (beat the market by 1.9%). The current 40.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.